The surging prevalence of prostate cancer, mounting geriatric population, and soaring number of government initiatives are expected to drive the U.S. prostate cancer treatment devices market at a CAGR of 5.6% during the forecast period (2020–2030).
Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/us-prostate-cancer-treatment-device-market-revenue/report-sample
The U.S. prostate cancer treatment devices market growth is driven by the surging incidence of prostate cancer in the country. The Centers for Disease Control and Prevention (CDC) says that prostate cancer is the most-prevalent cancer among the male residents of the country after non-melanoma skin cancer. It is also one of the major causes of cancer deaths among American men. Further, the American Cancer Society (ACS) estimates that the country will record 248,530 new cases of prostate cancer and 34,130 deaths from it in 2021.
Make an Enquiry Before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=us-prostate-cancer-treatment-device-market-revenue
The type segment of the U.S. prostate cancer treatment devices market is categorized into HIFU, radiation, cryotherapy, and surgery. In 2019, the radiation category generated the highest revenue owing to the high availability of radiation therapy devices, presence of numerous market players, and significant deployment of these systems. Furthermore, the category is also expected to demonstrate the fastest growth during the forecast period, primarily on account of the high acceptance and adoption of radiotherapy and the introduction of advanced equipment.
Thus, the growing prevalence of prostate cancer in the U.S. and increasing preference for radio-based RP will drive the demand for prostate cancer treatment devices in the country.
